Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases—Current Clinical Approach

In recent years, the importance of butyrate in prevention and health promotion in human health has been revealed and many publications have highlighted its role as a key component for intestinal functioning. Recent findings show that sodium butyrate has anti-inflammatory and immuno-modulatory activities in intestinal diseases and may be used in the therapy of intestinal diseases. Sodium butyrate mitigates mucosal inflammation and oxidative status, restores the damaged epithelial barrier, and modulates visceral sensitivity and intestinal motility. Novel forms of encapsulation are being developed to improve the effectiveness of sodium butyrate, as well as its palatability and patient's compliance METHODS: We conducted a comprehensive literature review. In this review, we discuss the utility, efficacy and safety of sodium butyrate preparations, including different microencapsulated forms in the management of main intestinal diseases, primarily inflammatory bowel diseases, irritable bowel syndrome and diverticular disease. . RESULTS AND CONCLUSIONS: Advanced microencapsulated sodium butyrate preparations seem to be an promising form that could be used as add-on therapy for intestinal diseases. Due to butyrate's rapid epithelial absorption and local activity in the digestive tract, clinical outcomes may depend not only on the active ingredient but also on the delivery technology, release profile, and dosage. Therefore, we suggest that clinical results should be assessed in relation to specific preparations. Our summary confirms that specific microencapsulated versions, including those utilizing the MSB^® technology are valuable therapeutic options supporting the treatment of intestinal diseases. Differences between clinical study results suggests that formulation of butyrate impacts its efficacy.